220 related articles for article (PubMed ID: 29059031)
1. Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature.
Wang B; Abbott L; Childs K; Taylor C; Agarwal K; Cormack I; Miquel R; Suddle A
Int J STD AIDS; 2018 Mar; 29(4):414-417. PubMed ID: 29059031
[TBL] [Abstract][Full Text] [Related]
2. Probable hepatotoxicity with dolutegravir: report of two cases and review of the literature.
Nhean S; Yoong D; Wong DK; Gough K; Tseng AL
AIDS; 2019 Jun; 33(7):1261-1263. PubMed ID: 31045944
[No Abstract] [Full Text] [Related]
3. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
Blanco JL; Rojas J; Paredes R; Negredo E; Mallolas J; Casadella M; Clotet B; Gatell JM; de Lazzari E; Martinez E;
J Antimicrob Chemother; 2018 Jul; 73(7):1965-1971. PubMed ID: 29608685
[TBL] [Abstract][Full Text] [Related]
5. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV.
Kandel CE; Walmsley SL
Drug Des Devel Ther; 2015; 9():3547-55. PubMed ID: 26185421
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir-associated hyperglycaemia in patients with HIV.
Lamorde M; Atwiine M; Owarwo NC; Ddungu A; Laker EO; Mubiru F; Kiragga A; Lwanga IB; Castelnuovo B
Lancet HIV; 2020 Jul; 7(7):e461-e462. PubMed ID: 32105626
[No Abstract] [Full Text] [Related]
8. Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study.
Briand C; Dollfus C; Faye A; Kantor E; Avettand-Fenoel V; Caseris M; Descamps D; Schneider V; Tabone MD; Vaudre G; Veber F; Blanche S; Frange P
J Antimicrob Chemother; 2017 Mar; 72(3):837-843. PubMed ID: 27999017
[TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability, and Efficacy of Generic Dolutegravir-containing Antiretroviral Therapy Regimens Among South Indian Human Immunodeficiency Virus-infected Patients.
Kumarasamy N; Prabhu S; Chandrasekaran E; Poongulali S; Pradeep A; Chitra D; Balakrishnan R; Benson CA
Clin Infect Dis; 2019 Mar; 68(6):1048-1051. PubMed ID: 30192925
[TBL] [Abstract][Full Text] [Related]
10. Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients.
Naeger LK; Harrington P; Komatsu T; Deming D
Antivir Ther; 2016; 21(6):481-488. PubMed ID: 26866979
[TBL] [Abstract][Full Text] [Related]
11. Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life.
Lattuada E; Lanzafame M; Nicolè S; Rigo F; Cucchetto G; Concia E; Vento S
Int J STD AIDS; 2018 Feb; 29(2):206-207. PubMed ID: 29320967
[No Abstract] [Full Text] [Related]
12. [Integrase inhibitor in HIV therapy. Does dolutegravir set new standards?].
MMW Fortschr Med; 2014 Jun; 156 Suppl 1():58-9. PubMed ID: 25026862
[No Abstract] [Full Text] [Related]
13. [Dolutegravir (Tivicay) orally].
J Pharm Belg; 2015 Sep; (3):47-8. PubMed ID: 26513835
[No Abstract] [Full Text] [Related]
14. Evaluation of dolutegravir safety for the treatment of HIV-1.
Keeshin SW; Feinberg J
Expert Opin Drug Saf; 2015 Jan; 14(1):141-7. PubMed ID: 25347230
[TBL] [Abstract][Full Text] [Related]
15. Severe Thrombocytopenia During Dolutegravir-containing Antiretroviral Therapy.
Nakaharai K; Miyajima M; Kobayashi H; Shimizu A; Hosaka Y; Horino T; Hori S
Intern Med; 2017 Aug; 56(16):2229-2232. PubMed ID: 28781310
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
Shah BM; Schafer JJ; Desimone JA
Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
[TBL] [Abstract][Full Text] [Related]
17. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.
Hoffmann C; Welz T; Sabranski M; Kolb M; Wolf E; Stellbrink HJ; Wyen C
HIV Med; 2017 Jan; 18(1):56-63. PubMed ID: 27860104
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of dolutegravir in treatment-experienced patients: the SAILING and VIKING trials].
Moreno S; Berenguer J
Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():26-30. PubMed ID: 25858609
[TBL] [Abstract][Full Text] [Related]
19. [Safety profile of dolutegravir].
Rivero A; Domingo P
Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():9-13. PubMed ID: 25858606
[TBL] [Abstract][Full Text] [Related]
20. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
